



JC10 Rec'd PCT/PTO 12 JUL 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ZLOKOVIC et al.

Appln. No. 10/537,545

Filed: June 3, 2005

Atty. Ref.: 4061-35

T.C. / Art Unit: Not Known

Examiner: Not Known

FOR: NEUROPROTECTIVE ACTIVITY OF ACTIVATED PROTEIN C INDEPENDENT OF ITS ANTICOAGULANT ACTIVITY

\* \* \*

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

July 12, 2005

Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement (IDS) of June 3, 2005, attached is a Form PTO-1449 listing U.S. patent documents and the enclosed.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.


As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.


Respectfully submitted,

**NIXON & VANDERHYTE P.C.**

By: \_\_\_\_\_

  
Gary B. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE  
CITATION**

APPLN. NO.

10/537,545

ATTY. DKT. NO.

4061-35

APPLICANT

ZLOKOVIC et al.

(Use several sheets if necessary)

FILING DATE

June 3, 2005

GROUP

Not Known

**U.S. PATENT DOCUMENTS**

*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR	4,775,624	10/1998	Bang et al.			
BR	5,084,274	01/1992	Griffin et al.			
VR	5,147,638	09/1992	Esmon et al.			
TR	5,151,268	09/1992	Bang et al.			
CR	5,196,322	03/1993	Bang et al.			
DR	5,202,253	04/1993	Esmon et al.			
ER	5,270,040	12/1993	Bang et al.			
FR	5,270,178	12/1993	Gerlitz et al.			
GR	5,279,956	01/1994	Griffin et al.			
HR	5,336,610	08/1994	Esmon et al.			
IR	5,350,578	09/1994	Griffin et al.			
JR	5,358,932	10/1994	Foster et al.			
KR	5,453,373	09/1995	Gerlitz et al.			
LR	5,580,962	12/1996	Eibl et al.			
MR	5,695,993	12/1997	Fukudome et al.			
NR	5,753,224	05/1998	Foster et al.			
OR	5,766,921	06/1998	Foster et al.			
PR	5,837,843	11/1998	Smirnov et al.			
QR	5,847,085	12/1998	Esmon et al.			
RR	5,852,171	12/1998	Fukudome et al.			
SR	5,863,896	01/1999	Rosing et al.			
TR	6,037,322	03/2000	Grinnell et al.			
UR	6,071,514	06/2000	Grinnell et al.			
VR	6,159,468	12/2000	Carlson et al.			
WR	6,162,629	12/2000	Baker et al.			
XR	6,268,337	07/2001	Grinnell et al.			
YR	6,344,197	02/2002	Fisher et al.			
ZR	6,395,270	05/2002	Carlson et al.			
AAR	6,399,064	06/2002	Fukudome et al.			
BBR	6,423,313	07/2002	Esmon et al.			

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

APPLN. NO.

10/537,545

ATTY. DKT. NO.

4061-35

APPLICANT

ZLOKOVIC et al.

(Use several sheets if necessary)

FILING DATE

June 3, 2005

GROUP

Not Known

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR	6,426,071	07/2002	Grinnell et al.			
BR	6,436,397	08/2002	Baker et al.			
CR	6,630,137	10/2003	Carlson et al.			
DR	6,630,138	10/2003	Gerlitz et al.			
ER	6,841,371	01/2005	Gerlitz et al.			
FR	2002/0028199	03/2002	Griffin et al.			
GR	2003/0220258	11/2003	Benner et al.			
HR	2005/0037964	02/2005	Griffin et al.			
IR						
JR						
KR						

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
LR					
MR					
NR					
OR					
PR					
QR					
RR					

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

SR	Cheng et al. "Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective" Nature Med. 9:338-342 (2003)
TR	Dömötör et al. "Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1" Blood 101:4797-4801 (2003)
UR	Fernández et al. "Recombinant murine-activated protein C is neuroprotective in a urine ischemic stroke model" Blood Cells Molecules, and Diseases 30:271-276 (2003)
VR	Griffin et al. "Activated protein C and ischemic stroke" Crit. Care Med. 32[Suppl.]:S247-S253 (2004)
WR	Guo et al. "Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3" Neuron 41:563-572 (2004)
XR	Liu et al. "Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C" Nat. Med. 10:1379-1383 (2004)
ZR	Shibata et al. "Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke" Circulation 103:1799-1805 (2001)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)